Form D · Biotechnology
Ambagon Therapeutics Inc.
Eindhoven, P7 · CIK 0001819934
Offering snapshot reported Feb 7, 2025 · SEC filing
- Reported sold
- $5M Offering amount: $12M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 24, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 7, 2025 | Initial | $5,000,000 | No comparison | 4 | SEC filing |
| Jun 1, 2022 | Amendment | $44,999,996 | $0vs Jan 19, 2022 | 9 | SEC filing |
| Jan 19, 2022 | Initial | $44,999,996 | No comparison | 9 | SEC filing |
| Dec 22, 2021 | Amendment | $5,399,998 | $0vs Aug 20, 2021 | 8 | SEC filing |
| Aug 20, 2021 | Amendment | $5,399,998 | No comparison | Not reported | SEC filing |
| Aug 3, 2020 | Initial | $7,199,998 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-537701
Series A-1 Preferred Stock and shares of the Company's Common Stock issuable upon the conversion thereof.
Source: Form D, filed Feb 7, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Michelle Arkin | Director |
| Lucas Brunsveld | Executive |
| Roel Bulthuis | Director |
| Margarita Chavez | Director |
| Scott Clarke | Director, Executive |
| Peter Dudek | Director |
| Melissa Mc Cracken | Director |
| Bryan Miller | Executive |
| Janwillem Naesens | Director |
| Christian Ottmann | Executive |
| Nancy Pryer | Executive |
| Adam Rosenberg | Director |
| Josh Seidenfeld | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
De Lismortel 31, Catalyst Business Ctr
Eindhoven, P7, 5612 AR
Eindhoven, P7, 5612 AR